CLIMB BIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CLIMB BIO, INC. (CLYM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.48M, a 46.20% increase year-over-year.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.60M, a 20.62% decline year-over-year.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.98M, a 36.07% increase year-over-year.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.01M, a 97.85% increase year-over-year.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.05M, a 44.93% increase from fiscal 2024.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $5.56M, a 56.61% decline from fiscal 2023.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $12.81M, a 83.18% increase from fiscal 2022.
- CLIMB BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.99M, a 87.08% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.48M 10-Q · filed 2026-08-06 | $3.09M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $1.60M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $8.05M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $3.98M 10-Q · filed 2025-11-06 | $4.99M derived: sum of 2 quarters · filed 2026-08-06 | $7.01M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $1.01M 10-Q · filed 2026-08-06 | $3.04M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $2.02M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $5.56M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $2.92M 10-Q · filed 2025-11-06 | $3.43M derived: sum of 2 quarters · filed 2025-11-06 | $3.90M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $512.00K 10-Q · filed 2025-11-06 | $977.00K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $465.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $12.81M 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $656.00K 10-Q · filed 2024-11-12 | $1.43M derived: sum of 2 quarters · filed 2024-11-12 | $11.60M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $777.00K 10-Q · filed 2024-11-12 | $10.95M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $10.17M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $6.99M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $1.78M 10-Q · filed 2023-11-14 | $3.56M derived: sum of 2 quarters · filed 2023-11-14 | $5.10M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.77M 10-Q · filed 2023-11-14 | $3.31M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $1.54M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $3.74M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $1.24M 10-Q · filed 2022-11-14 | $2.29M derived: sum of 2 quarters · filed 2022-11-14 | $2.58M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $1.05M 10-Q · filed 2022-11-14 | $1.35M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $297.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $707.00K 10-K · filed 2022-03-07 | |||
| 2020-09-30 | $49.00K 10-Q · filed 2021-11-08 | $100.00K derived: sum of 2 quarters · filed 2021-11-08 | $234.00K derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $51.00K 10-Q · filed 2021-11-08 | $185.00K derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $134.00K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |